Fluoxetine therapy in obese diabetic and glucose intolerant patients.
A double-blind placebo-controlled trial was conducted, involving 97 obese diabetic and glucose intolerant patients receiving either 60 mg fluoxetine daily (47 patients) or a placebo (50 patients); a similar calorie-restricted diet was prescribed to all patients. Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved. Drop-out rate was not significantly different for both groups of patients.
Kutnowski
M
M
Hôpital Universitaire Brugmann, Department of Internal Medicine, ULB, Brussels, Belgium.
Daubresse
J C
JC
Friedman
H
H
Kolanowski
J
J
Krzentowski
G
G
Scheen
A
A
Van Gaal
L
L
D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000503:physiopathology*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D015431:Weight Loss
D001786:Blood Glucose; D005473:Fluoxetine; D006442:Glycated Hemoglobin; D007328:Insulin; D010919:Placebos